Skip to main content
. 2020 Dec 10;10:21762. doi: 10.1038/s41598-020-78646-y

Figure 2.

Figure 2

The antiproliferative effect of treatment with fulvestrant and lapatinib is limited in MDA-MB-361 cell line. (a) Antiproliferative activity of fulvestrant and lapatinib, alone and in combination, in ER+/HER2+ breast cancer cell lines with and without PIK3CA mutations. BT474 (left) and MDA-MB-361 (right) cells were used as representative PIK3CA-wild-type and PIK3CA-mutant ER+/HER2 breast cancer cell lines, respectively. Cells were treated with DMSO (black), fulvestrant (100 nM, green), or lapatinib (100 nM, blue), alone and in combination (red), for 0, 2, 4, and 8 days (mean ± standard deviation [SD; n = 3]). Relative levels of ATP were calculated by chemiluminescence assay and compared with the chemiluminescence of DMSO on day 0. (b) Comparison of the effect in each drug treatment between BT474 and MDA-MB-361 cell lines. Differences on day 8 were analyzed using Student’s t-test. The data represent the mean ± SD (n = 3). F, Fulvestrant; L, Lapatinib.